Clearpoint Neuro Inc Stock Price, News & Analysis

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced plans to release its financial results for the fourth quarter and full year of 2022 on March 1, 2023, after market close. Investors and analysts can join a live broadcast at 4:30 p.m. ET to discuss these results. The call will be accessible via telephone and an online archive will be available on the Company’s Investor website. ClearPoint Neuro aims to enhance treatment for neurological disorders through its Neuro Navigation System, which has FDA clearance and is utilized in over 65 sites globally. The Company emphasizes its partnerships and the importance of its innovative therapies for complex neurological conditions.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced its preliminary financial results for Q4 and full year 2022. Q4 revenue reached $5.2 million, a 21% increase year-over-year, while full-year revenue was $20.6 million, up 26%. Cash burn for Q4 was approximately $3.0 million, with cash reserves of $37.5 million at year-end. The company forecasts 2023 revenue between $25.0 million and $27.0 million, citing growth driven by new clinical trials and product developments. CEO Joe Burnett noted a record backlog of orders for a promising 2023.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) has initiated a clinical trial for Glioblastoma, enrolling its first patient at Skåne University Hospital in Lund, Sweden. This trial assesses the safety and feasibility of the ClearPoint Prism™ Neuro Laser Therapy System for tumor ablation in five patients. The system combines navigation and laser technology for minimally invasive procedures. Following FDA clearance received in September, data from this trial will also assist in obtaining CE Mark in Europe. ClearPoint aims to improve treatment options for neurological disorders.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced its participation in upcoming investor conferences. Management will present at the 2022 Stifel Healthcare Conference on November 15, 2022, at 10:55 a.m. ET in New York, and at the 34th Annual Piper Sandler Healthcare Conference on November 29, 2022, at 11:50 a.m. ET, also in New York. ClearPoint Neuro focuses on enabling therapies for complex neurological disorders, with its navigation system having FDA clearance and operational at over 60 sites globally.

ClearPoint Neuro reported third-quarter 2022 revenue of $5.1 million, reflecting a 13% year-over-year increase. Key achievements include the European Commission granting full marketing authorization for Upstaza, a gene therapy, and multiple FDA clearances for new products. The company anticipates full-year revenues between $21.0 million and $22.0 million. However, operating expenses rose to $7.5 million, attributed to increased headcount and share-based compensation, leading to a decrease in cash reserves from $54.1 million at the beginning of the year to $40.5 million.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) is set to release its financial results for Q3 2022 on November 8, 2022, after market close. A live broadcast of the results will occur at 4:30 p.m. Eastern time the same day. Investors can access the call online or by phone. ClearPoint's current offerings include advanced navigation and delivery systems for treating neurological disorders, and the company maintains partnerships with over 45 organizations in clinical trials. Investors are reminded of uncertainties affecting future performance, including market acceptance and supply chain issues.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced that its Swedish partner, Clinical Laserthermia Systems (CLS), has received 510(k) clearance for its laser, facilitating the launch of the ClearPoint Prism™ Neuro Laser Therapy System. This system, designed for soft tissue necrosis through MRI-guided thermal therapy, combines the ClearPoint navigation platform and CLS laser technology. Currently, it is in limited market release across select U.S. academic medical centers. ClearPoint aims to enhance treatment accessibility for neurological diseases through this innovative solution.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the appointment of Mazin Sabra as Chief Operating Officer, effective October 10. Reporting to CEO Joe Burnett, Sabra brings extensive experience in quality, procurement, and supply chain management from Philips and Stryker. His leadership is anticipated to strengthen ClearPoint's operational infrastructure and enhance confidence among pharma and device partners. ClearPoint Neuro is dedicated to delivering therapies for neurological disorders and has a robust product portfolio including the ClearPoint Neuro Navigation System.

ClearPoint Neuro announced 510(k) clearance for version 2.1 of its Neuro Navigation software, enhancing stereotactic guidance for neurological procedures within MRI environments. This update includes improved usability for clinicians, new trajectory planning tools, and enhanced visualization capabilities. Currently in limited market release, the software will first be available to customers in the ClearPoint 'Pathfinder' Program. The company aims to optimize clinical workflows and support future innovations in preoperative planning and medical imaging.